Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Faquim-Mauro, E. L.
Right arrow Articles by Macedo, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faquim-Mauro, E. L.
Right arrow Articles by Macedo, M. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol. 12, No. 12, 1733-1740, December 2000
© 2000 Japanese Society for Immunology

Induction of IL-4-dependent, anaphylactic-type and IL-4-Independent, non-anaphylactic-type IgG1 antibodies is modulated by adjuvants

Eliana L. Faquim-Mauro and Mahasti S. Macedo

Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, Avenue Professor Lineu Prestes 1730, 05508-900 São Paulo, Brazil

Correspondence to: M. S. Macedo

Adjuvants can modulate the levels of anaphylactic- and non-anaphylactic-type IgG1 antibodies produced in response to a particular antigen. Mice immunized with ovalbumin (OVA) in Al(OH)3 gel (alum) produced mostly the anaphylactic type, irrespective of the s.c. or i.p. route used, and this antibody was not detectable in IL-4–/– mice. In contrast, when OVA was injected in complete Freund's adjuvant (CFA), it induced substantial amounts of non-anaphylactic-type IgG1 in both IL-4+/+ and IL-4–/– mice, and some anaphylactic IgG1 antibody in IL-4+/+ mice only. When IFN-{gamma} was neutralized by specific mAb in wild-type mice immunized with OVA in CFA, the anaphylactic-type IgG1 antibody increased reaching the same levels as in alum-injected mice. This result indicates that the induction of IFN-{gamma} by the immunization with CFA down-regulates the production of IL-4-dependent, anaphylactic-type IgG1. Despite their different effects on IgG1 antibody production, both adjuvants dramatically increased the production of IgG2a in IL-4-deprived mice and did not induce any detectable IgE in these mice.

Keywords: anaphylaxis, cytokine, humoral response, immunomodulation

Transmitting editor: Z. Ovary


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. R. Silva, A. Casabuono, J. F. Jacysyn, B. C. Favoretto, I. Fernandes, M. S. Macedo, A. S. Couto, and E. L. Faquim-Mauro
Sialic Acid Residues Are Essential for the Anaphylactic Activity of Murine IgG1 Antibodies
J. Immunol., December 15, 2008; 181(12): 8308 - 8314.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. A. Marshall, A. M. Grierson, P. Garside, W. Harnett, and M. M. Harnett
ES-62, an Immunomodulator Secreted by Filarial Nematodes, Suppresses Clonal Expansion and Modifies Effector Function of Heterologous Antigen-Specific T Cells In Vivo
J. Immunol., November 1, 2005; 175(9): 5817 - 5826.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. E. Smith, T. N. Eagar, J. L. Strominger, and S. D. Miller
Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis
PNAS, July 5, 2005; 102(27): 9595 - 9600.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
J. Cote-Sierra, A. Bredan, C. M. Toldos, B. Stijlemans, L. Brys, P. Cornelis, M. Segovia, P. de Baetselier, and H. Revets
Bacterial Lipoprotein-Based Vaccines Induce Tumor Necrosis Factor-Dependent Type 1 Protective Immunity against Leishmania major
Infect. Immun., January 1, 2002; 70(1): 240 - 248.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.